Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol.
Wasan
K M
KM
Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.
Conklin
J S
JS
D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity*; D000935:Antifungal Agents / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity*; D008076:Cholesterol, HDL / Q000032:analysis / Q000097:blood; D008078:Cholesterol, LDL / Q000032:analysis / Q000097:blood / Q000378:metabolism*; D002846:Chromatography, Affinity; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000150:complications* / Q000188:drug therapy*
D000935:Antifungal Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000666:Amphotericin B